First Brands Group debt targeted by Apollo Global Management - report
Paula Green, SVP of Human Resources at Twist Bioscience Corp (NASDAQ:TWST), sold 892 shares of common stock on September 8, 2025, at a price of $25.76, for a total transaction value of $22,977. The transaction occurs as TWST shares trade near their 52-week low of $24.28, having declined 46% year-to-date.
Following the transaction, Green directly owns 124,837 shares of Twist Bioscience Corp. The $1.5 billion biotech company maintains strong liquidity with a current ratio of 3.9 and more cash than debt on its balance sheet. InvestingPro analysis reveals additional key metrics and insights about TWST’s financial health.
In other recent news, Twist Bioscience reported its Q3 2025 earnings, revealing an 18% increase in revenue to $96.1 million compared to the same period last year. Despite this growth, the company recorded an adjusted EBITDA loss of $8 million, although this was an improvement from the previous fiscal year. In a strategic move, Twist Bioscience appointed Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. Blake brings extensive experience from her previous role as CEO of Vistaprint, where she significantly increased the company’s revenue.
JPMorgan recently lowered its price target for Twist Bioscience to $25 from $33, maintaining an Underweight rating. Meanwhile, TD Cowen adjusted its price target to $36 from $58, citing changes in the company’s fiscal year 2025 guidance due to a shift in Next-Generation Sequencing revenue. Evercore ISI also reduced its price target to $46 from $50, while maintaining an Outperform rating, following strong performance in the Next-Generation Sequencing segment. These recent developments highlight the dynamic landscape surrounding Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.